Support NET Research
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading funder of neuroendocrine tumor (NET) research, having funded more than $36 million in research projects aimed at advancing improved treatments for neuroendocrine tumors. NETRF funds are solely provided by private donations from around the globe. There are many ways to support neuroendocrine tumor (NET) research, such a making a gift, volunteering, or hosting a fundraising event. We hope that the information you find on this page is helpful and will entice you to take the next step in getting involved with NETRF.
Your gift will fund world-class research, empower and educate NET survivors and families and bolster the field of NET research. Learn more about the impact of your gift .
The latest in NET News
NETRF Research News August 2024
Welcome to NETRF’s inaugural Research News. This quarterly newsletter features updates on NETRF funded-projects, new clinical trials, and related scientific developments.
Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface
Honoring Leadership: Drs. Shivdasani, Fisher, and Chung Named BOSA Emeritus Members
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).